<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30200140</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>36</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Establishment of normal reference values of NT-proBNP and its application in diagnosing acute heart failure in children with severe hand foot and mouth disease [corrected].</ArticleTitle><Pagination><StartPage>e12218</StartPage><MedlinePgn>e12218</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012218</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD), caused by enteroviruses, is an acute contagious disease in children. Some severe infections caused by human enterovirus 71 (HEV71) lead to rapid death in children with acute heart failure (HF). N-terminal probrain natriuretic peptide (NT-proBNP) is an important indicator of HF; however, its normal reference values in children and role in HFMD remain unclear.This study aimed to investigate the correlation between NT-proBNP and heart function and establish normal reference values of NT-proBNP in children with HFMD aged 0 to 18 years.In this study, 95% normal reference values were established in 1031 healthy children aged 0 to 18 years. The correlation between NT-proBNP and left ventricular ejection (LVEF) was analyzed in 392 children with HFMD using Spearman correlation and receiver operating characteristic analysis.NT-proBNP levels were negatively correlated with LVEF in 392 children with HFMD. The median NT-proBNP level was 921&#x200a;pg/mL in the early cardiorespiratory failure group, but only 55&#x200a;pg/mL in the nervous system involvement group. Serum NT-proBNP levels were negatively correlated with age. The normal reference value in the neonatal period (0 to &lt;1 month) and adolescence (13-18 years) was 250.0 to 3987.0&#x200a;pg/mL and 20.0 to 145.0&#x200a;pg/mL, respectively.NT-proBNP levels can reflect the severity of HFMD and discriminate the second stage from the third stage of HFMD effectively. NT-proBNP is a useful biomarker to predict the early stage of severe HFMD in children with HF. Different ages fit with different normal reference values of NT-proBNP in children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Sai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School Of Basic Medical Science, Central South University Clinical Laboratory ICU Department of Infections, Hunan Children's Hospital, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Zhenghui</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liping</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Suwu</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Junming</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Boli</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Liya</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shiping</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Medicine (Baltimore). 2020 Mar;99(12):e19688. doi: 10.1097/MD.0000000000019688</RefSource><PMID Version="1">32195975</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30200140</ArticleId><ArticleId IdType="pmc">PMC6133461</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000012218</ArticleId><ArticleId IdType="pii">00005792-201809070-00082</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kok CC. Therapeutic and prevention strategies against human enterovirus 71 infection. World J Virol 2015;4:78&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419123</ArticleId><ArticleId IdType="pubmed">25964873</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M, El Khatib NF, Tu S, et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol 2012;53:285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>National Bureau of Statistics of the People's Republic of China. Statistical Yearbook of China; 2012 (China Statistics Press, 2013).</Citation></Reference><Reference><Citation>Escobar C, Santiago-Ruiz JL, Manzano L. Diagnosis of heart failure in elderly patients: a clinical challenge. Eur J Heart Fail 2011;13:1152author reply 1152-1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">21852308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel A, Empe K, Dorr M, et al. De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int 2015;112:298&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452901</ArticleId><ArticleId IdType="pubmed">26008893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad T, O&#x2019;Connor CM. Therapeutic implications of biomarkers in chronic heart failure. Clin Pharmacol Ther 2013;94:468&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">23856627</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10988264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 2008;41:210&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18048022</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko GI, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16040618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto M, Manabe H, Nakau K, et al. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. Correlation with the heart failure score and comparison with B-type natriuretic peptide. Circ J 2010;74:998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">20378998</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwachtgen L, Herrmann M, Georg T, et al. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005;94:399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">15940440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18600369</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647136</ArticleId><ArticleId IdType="pubmed">16412859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12127613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai K, Hata K, Tanaka K, et al. Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging. Am J Cardiol 2004;93:719&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019876</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18154959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerer-Lercher A, Ludwig W, Falkensammer G, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004;50:1174&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15142976</ArticleId></ArticleIdList></Reference><Reference><Citation>Fradley MG, Larson MG, Cheng S, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011;108:1341&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209520</ArticleId><ArticleId IdType="pubmed">21864812</ArticleId></ArticleIdList></Reference><Reference><Citation>Nir A, Bar-Oz B, Perles Z, et al. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004;93:603&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174780</ArticleId></ArticleIdList></Reference><Reference><Citation>Long L, Xu L, Xiao Z, et al. Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease. Sci Rep 2016;6:23444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802311</ArticleId><ArticleId IdType="pubmed">27001010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa A, Seino Y, Yamashita T, et al. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006;70:1372&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17062956</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HL, Zhang YF, Li YP, et al. N-terminal pro-brain natriuretic peptide levels associated with severe hand, foot and mouth disease. BMC Infect Dis 2016;16:585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5069980</ArticleId><ArticleId IdType="pubmed">27760526</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Lu X, Liu P, et al. N-terminal pro-B-type natriuretic peptide for the prognostic prediction of severe enterovirus 71-associated hand, foot, and mouth disease. Int J Infect Dis 2017;54:64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">27818360</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron MB, Holcomb PH, Dawson CA, et al. Edema development and recovery in neurogenic pulmonary edema. J Appl Physiol (1985) 1994;77:1155&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">7836117</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YC, Chi CS, Lin NN, et al. Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. Pediatr Cardiol 2006;27:577&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16933070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu WH, Hsieh KS, Lu PJ, et al. Hexamethonium reverses the lethal cardiopulmonary damages in a rat model of brainstem lesions mimicking fatal enterovirus 71 encephalitis. Crit Care Med 2013;41:1276&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">23388515</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudson JD, Cabrera AG. The pathophysiology of heart failure in children: the Basics. Curr Cardiol Rev 2016;12:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861948</ArticleId><ArticleId IdType="pubmed">26585040</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>